H.C. Wainwright Maintains a Buy Rating on Iterum Therapeutics (ITRM)

By Carrie Williams

H.C. Wainwright analyst Ed Arce maintained a Buy rating on Iterum Therapeutics (ITRMResearch Report) today and set a price target of $9.00. The company’s shares closed last Thursday at $3.50.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 14.9% and a 43.7% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.

Iterum Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.00, a 134.6% upside from current levels. In a report released yesterday, Needham also assigned a Buy rating to the stock with a $7.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $7.65 and a one-year low of $1.40. Currently, Iterum Therapeutics has an average volume of 52.43K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Iterum Therapeutics Plc is a clinical-stage pharmaceutical company, which engages in the development and commercialization of treatments for drug resistant bacterial infections. It focuses on sulopenem program that offer a solution to the problem of antibiotic resistance, and the toxicity limitations of existing agents. It operates through the Ireland and Unites States geographical segments. The company was founded by Corey N. Fishman on June 24, 2015 and is headquartered in Dublin, Ireland.